UK-based biotech firm Phenotypeca is partnering with the Bill & Melinda Gates Foundation on a project to produce albumin at an affordable price. The move is aimed at making life-saving vaccines more accessible and cheaper for wider use globally. Developing a vaccine from concept to market can cost between $200m and $500m and it can take five to 18 years to bring it to market. The foundation is hoping to make supply readily available and provide more affordable albumin to vaccine producers, reducing costs for end users in low- and middle-income countries.
Exclusive: Aussie mortgage broker Finsure confirms ‘cyber incident’ impacting customers and brokers – Cyber Daily
Australian mortgage broker Finsure has confirmed a cyber incident affecting customers and brokers. The company is working to address the issue and is taking steps
